TNFRSF17 and plasma cell myeloma: For example, Arcellx Inc. announced the phase 1 clinical data of their B cell maturation antigen (BCMA)-targeted CAR-T therapy for the treatment of multiple myeloma (NCT04155749) in April 2022.